Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US7915273B2 · kind B2 · utility

32Cited by

0References

2Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Ankush Argade · Foster City, US
Arvinder Sran · Fremont, US
David Carroll · San Francisco, US
Jeffrey Clough · Redwood City, US
Kin Tso · San Francisco, US
Somasekhar Bhamidipati · Foster City, US
Sambaiah Thota · Fremont, US
Rajinder Singh · Belmont, US
Vanessa Taylor · San Francisco, US
Hui Li · Santa Clara, US
Esteban Masuda · Menlo Park, US

Key dates

Filing date	Feb 24, 2010
Grant date	Mar 29, 2011
Priority date	—
Expiry date	Feb 24, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.